BidaskClub lowered shares of Simulations Plus (NASDAQ:SLP) from a strong-buy rating to a buy rating in a research note released on Wednesday morning.
Several other research analysts have also commented on SLP. Zacks Investment Research lowered shares of Simulations Plus from a buy rating to a hold rating in a research note on Friday, March 23rd. ValuEngine raised shares of Simulations Plus from a hold rating to a buy rating in a research note on Monday, April 2nd.
Shares of SLP opened at $19.00 on Wednesday. Simulations Plus has a 1-year low of $11.45 and a 1-year high of $19.55. The stock has a market cap of $329.19 million, a price-to-earnings ratio of 47.50 and a beta of -0.56.
Simulations Plus (NASDAQ:SLP) last announced its quarterly earnings results on Monday, April 9th. The technology company reported $0.11 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.11. Simulations Plus had a net margin of 30.65% and a return on equity of 26.19%. The business had revenue of $7.36 million during the quarter, compared to analysts’ expectations of $7.37 million. equities research analysts anticipate that Simulations Plus will post 0.4 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, May 2nd. Stockholders of record on Wednesday, April 25th were paid a $0.06 dividend. This represents a $0.24 annualized dividend and a dividend yield of 1.26%. The ex-dividend date was Tuesday, April 24th. Simulations Plus’s payout ratio is 70.59%.
In related news, CFO John Robert Kneisel sold 2,991 shares of Simulations Plus stock in a transaction that occurred on Friday, April 20th. The shares were sold at an average price of $17.64, for a total value of $52,761.24. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Chairman Walter S. Woltosz sold 18,500 shares of Simulations Plus stock in a transaction that occurred on Tuesday, March 27th. The stock was sold at an average price of $14.54, for a total transaction of $268,990.00. Following the completion of the transaction, the chairman now owns 5,466,408 shares of the company’s stock, valued at approximately $79,481,572.32. The disclosure for this sale can be found here. In the last three months, insiders sold 58,491 shares of company stock valued at $938,356. Insiders own 33.45% of the company’s stock.
A number of institutional investors have recently modified their holdings of the stock. BlackRock Inc. lifted its stake in Simulations Plus by 0.8% in the fourth quarter. BlackRock Inc. now owns 760,779 shares of the technology company’s stock worth $12,249,000 after acquiring an additional 6,194 shares during the last quarter. Renaissance Technologies LLC lifted its stake in Simulations Plus by 2.8% in the fourth quarter. Renaissance Technologies LLC now owns 525,100 shares of the technology company’s stock worth $8,454,000 after acquiring an additional 14,100 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in Simulations Plus by 8.6% in the first quarter. Dimensional Fund Advisors LP now owns 475,216 shares of the technology company’s stock worth $7,009,000 after acquiring an additional 37,811 shares during the last quarter. Crawford Investment Counsel Inc. lifted its stake in Simulations Plus by 2.7% in the first quarter. Crawford Investment Counsel Inc. now owns 387,614 shares of the technology company’s stock worth $5,717,000 after acquiring an additional 10,034 shares during the last quarter. Finally, Ancora Advisors LLC lifted its stake in Simulations Plus by 12.9% in the first quarter. Ancora Advisors LLC now owns 296,837 shares of the technology company’s stock worth $4,378,000 after acquiring an additional 33,925 shares during the last quarter. Institutional investors own 32.68% of the company’s stock.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), and pharmacodynamics of drugs administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments, which measure the rate of dissolution of the drug and additives in a dosage form; and MembranePlus, which simulates laboratory experiments.
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.